Download PDF
Horm Metab Res 2002; 34(5): 229-233
DOI: 10.1055/s-2002-32134
Original Basic
© Georg Thieme Verlag Stuttgart · New York

Somatostatin, but not Somatostatin Receptor Subtypes 2 and 5 Selective Agonists, Inhibits Calcitonin Secretion and Gene Expression in the Human Medullary Thyroid Carcinoma Cell Line, TT

M.  C.  Zatelli 1 , F.  Tagliati 1 , J.  E.  Taylor 2 , D.  Piccin 1 , M.  D.  Culler 2 , E.  C.  degli Uberti 1
  • 1Section of Endocrinology, Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, Ferrara, Italy
  • 2 Biomeasure Incorporated, Milford, MA, USA
Further Information

Publication History

13 November 2001

29 January 2002

Publication Date:
10 June 2002 (online)

Also available at
    Permissions and Reprints

Abstract

Somatostatin (SRIH) analogs are commonly used to treat symptoms in medullary thyroid carcinoma (MTC), that expresses SRIH receptors (SSTR1 to SSTR5), as does the human MTC cell line TT. The aim of this work was to evaluate whether SRIH, SSTR2 and SSTR5-selective agonists influence calcitonin (CT) secretion and gene expression in the TT cell line. CT secretion was evaluated by chemiluminescence, and gene expression was analyzed by Northern blot. TT cell line proliferation was also assessed by [3H] thymidine ([3H]thy) incorporation and viable cell number count. SRIH significantly (p < 0.05) reduced [3H]thy incorporation (approx. 50 %), viable cell number (approx. 20 %), CT secretion (- 30 %) and CT gene expression (approx. 2-fold). Exposure to the SSTR2-selective agonist, BIM-23 120, and to the SSTR5-selective agonist, BIM-23 206, did not modify CT secretion and mRNA levels in TT cells. Thus, SRIH inhibits DNA synthesis, cell proliferation, CT secretion and CT gene expression in the TT cell line, while SSTR2 and 5 selective agonists, although influencing DNA synthesis and cell proliferation, do not modify CT gene expression, suggesting that SRIH may influence gene expression acting through SSTRs other than subtypes 2 and 5. Furthermore, these findings may explain the erratic response of MTC patients in terms of CT plasma levels to treatment with SRIH analogs, like octreotide and lanreotide, which interact mainly with SSTR2 and 5.

Key words

Somatostatin - Somatostatin Receptors - Medullary Thyroid Carcinoma - Calcitonin Secretion - Gene Expression

References

  • 1 Hofland L J, Lamberts S WJ. Somatostatin receptors and disease: role of receptor subtypes. Baill.  Clin Endocrinol Metab. 1996;  10 163-176
    PubMedGoogle Scholar
  • 2 Patel Y C. Somatostatin and its receptor family.  Front Neuroendocrinology. 1999;  20 157-198
    PubMedGoogle Scholar
  • 3 Lauder H, Sellers L A, Fan T-P, Feniuk W, Humphrey P P. Somatostatin sst5 inhibition of receptor mediated regeneration of rat aortic vascular smooth muscle cells.  Br J Pharmacol. 1997;  122 663-670
    CrossrefPubMedGoogle Scholar
  • 4 Chiefari E, Crocetti U, Tardio B, Arturi F, Russo D, Trischitta V, Filetti S, Zingrillo M. A large family with hereditary MTC: role of RET genetic analysis in differential diagnosis between MEN2A and FMTC.  Horm Metab Res. 2000;  33 52-56
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Hanna F WF, Ardill J ES, Johnston C F, Cunningham R T, Curry W J, Russell C FJ, Buchanan F WF. Regulatory peptides and other neuroendocrine markers in medullary thyroid carcinoma of the thyroid.  J Endocrinol. 1997;  152 275-281
    CrossrefPubMedGoogle Scholar
  • 6 Oosterom R, Verleun T, Bruining H A, Hackeng W H, Lamberts S W. Human medullary thyroid carcinoma in tissue culture: secretion of calcitonin and carcinoembryonic antigen.  J Endocrinol Invest. 1987;  10 117-121
    PubMedGoogle Scholar
  • 7 Mato E, Matias-Guiu X, Chico A, Webb S M, Cabezas R, Bernà L, de Leiva A. Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma.  J Clin Endocrinol Metab. 1998;  83 2417-2420
    CrossrefPubMedGoogle Scholar
  • 8 Papotti M, Kumar U, Volante M, Pecchioni C, Patel Y C. Immunohistochemical detection of somatostatin receptor types 1 - 5 in medullary thyroid carcinoma of the thyroid.  Clin Endocrinol. 2001;  54 641-649
    CrossrefPubMedGoogle Scholar
  • 9 Bertagna X Y, Bloomgarden Z T, Rabin D, Roberts L J, Orth D N. Molecular weight forms of immunoreactive calcitonin in a patient with medullary carcinoma of the thyroid: dynamic studies with calcium, pentagastrin and somatostatin.  Clin Endocrinol. 1980;  13 115-123
    PubMedGoogle Scholar
  • 10 Vitale G, Tagliaferri P, Caraglia M, Rampone E, Ciccarelli A, Bianco A R, Abbruzzese A, Lupoli G. Slow release lanreotide in combination with Interferon-a2b in the treatment of symptomatic advanced medullary thyroid carcinoma.  J Clin Endocrinol Metab. 2000;  85 983-988.
    CrossrefPubMedGoogle Scholar
  • 11 Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abruzzese A, Tagliaferri P, Lupoli G. Current approaches and perspectives in the therapy of medullary thyroid carcinoma.  Cancer. 2001;  91 1797-1808
    CrossrefPubMedGoogle Scholar
  • 12 Modigliani E, Cohen R, Joannidis S, Siame-Mourot C, Giuliana J M, Charpentier G, Cassuto D, Bentata Passayre M, Tabarin A, Roger P, Caron P, Guillausseau P J, Lalau J D, Tourniaire J, Bayard F, Aufevre P, James-Deidier A, Calmettes C. Results of long term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma.  Clin Endocrinol. 1992;  36 183-186
    PubMedGoogle Scholar
  • 13 Lupoli G, Cascone E, Arlotta F, Vitale G, Celentano L, Salvatore M, Lombardi G. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon α-2b and octreotide.  Cancer. 1996;  78 1114-1118
    CrossrefPubMedGoogle Scholar
  • 14 Zatelli M C, Tagliati F, Taylor J E, Rossi R, Culler M D, degli Uberti E C. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT.  J Clin Endocrinol Metab. 2001;  86 2161-2169
    CrossrefPubMedGoogle Scholar
  • 15 Zabel M, Seidel J, Kaczmarek A, Surdyk-Zasada J, Grzeszkowiak J, Gorny A. Hybridocytochemical and immuno-ultrastructural study of calcitonin gene expression in cultured medullary carcinomas cells.  Histochemistry. 1992;  102 323-327
    PubMedGoogle Scholar
  • 16 Shimon I, Taylor J E, Dong J Z, Bitonte R A, Kim S, Morgan B, Coy D H, Culler M D, Melmed S. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid stimulating hormone, and prolactin regulation.  J Clin Invest. 1997;  99 789-798
    CrossrefPubMedGoogle Scholar
  • 17 degli Uberti E C, Hanau S, Rossi R, Piva R, Margutti A, Trasforini G, Pansini G, del Senno L. Somatostatin reduces 3H-thymidine incorporation and c-myc, but not thyroglobulin ribonucleic acid levels in human thyroid follicular cells in vitro.  J Clin Endocrinol Metab. 1991;  72 1364-1371
    PubMedGoogle Scholar
  • 18 Khosla S, Oursler M J, Schroeder M J, Eberhardt N L. Transforming growth factor-β 1 induces growth inhibition of a human medullary thyroid carcinoma cell line despite an increase in steady state c-myc messenger ribonucleic acid levels.  Endocrinology. 1994;  135 1887-1893
    CrossrefPubMedGoogle Scholar
  • 19 Buscail L, Esteve J P, Saint-Laurent N, Bertrand V, Reisine T, O’Carroll A M, Bell G I, Schally A V, Vaysse N, Susini C. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms.  Proc Natl Acad Sci USA. 1995;  92 1580-1584
    CrossrefPubMedGoogle Scholar
  • 20 Buscail L, Delesque N, Esteve J P, Saint-Laurent N, Prats H, Clerc P, Robberecht P, Bell G I, Liebow C, Schally A V, Vaysse N, Susini C. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2.  Proc Natl Acad Sci USA. 1994;  91 2315-2319
    CrossrefPubMedGoogle Scholar
  • 21 Florio T, Yao H, Carey K D, Dillon T J, Stork P J. Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1).  Mol Endocrinol. 1999;  13 24-37
    CrossrefPubMedGoogle Scholar
  • 22 Sharma K, Patel Y C, Srikant C B. C-terminal region of human somatostatin receptor five is required for induction of Rb and Gi cell cycle arrest.  Mol Endocrinol. 1999;  13 82-90
    CrossrefPubMedGoogle Scholar
  • 23 Sharma K, Patel Y C, Srikant C B. Subtype selective induction of p53-dependent apoptosis but not cell cycle arrest by human somatostatin receptor 3.  Mol Endocrinol. 1996;  10 1688-1696
    CrossrefPubMedGoogle Scholar
  • 24 de Bustros A, Ball D W, Peters R, Compton D, Nelkin B D. Regulation of human calcitonin gene transcription by cyclic AMP.  Biochem Biophys Res Commun. 1992;  189 1157-1164
    CrossrefPubMedGoogle Scholar
  • 25 Patel Y C, Murthy K K, Escher E, Banville D, Spiess J, Srikant C B. Mechanisms of action of somatostatin: an overview of receptor function and studies of the molecular characterization and purification of somatostatin receptor proteins.  Metabolism. 1990;  39 (Suppl. 2) 63
    CrossrefPubMedGoogle Scholar
  • 26 Mekonnen Y, Raue F, Zink A, Ziegler R. Long-term exposure to SMS 201 - 995 inhibits proliferation and calcitonin release in neoplastic C-cells.  Horm Metab Res. 1993;  25 528-531
    PubMedGoogle Scholar

E. C. degli Uberti, M.D.

Section of Endocrinology · Dept. of Biomedical Sciences and Advanced Therapies · University of Ferrara

Via Savonarola 9 · 44100 Ferrara · Italy ·

Phone: + 39 (532) 23 66 82 ·

Fax: + 39 (532) 23 65 14

Email: ti8@dns.unife.it

      >